Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Kidney Function and Fracture Risk: The Atherosclerosis Risk in Communities (ARIC) Study

(2016) Natalie R. Daya et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Frailty and Sarcopenia as Predictors of Adverse Health Outcomes in Persons With Diabetes Mellitus

(2016) Anthony P. Liccini et al.   Journal of the American Medical Directors Association

Frailty as a Major Factor in the Increased Risk of Death and Disability in Older People With Diabetes

(2016) Marta Castro-Rodríguez et al.   Journal of the American Medical Directors Association

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetes in Older Adults

(2012) M. S. Kirkman et al.   DIABETES CARE

Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)

(2012) Ishan Hirji et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

(2011) Frank A. Holtkamp et al.   KIDNEY INTERNATIONAL

Preventing and treating dehydration in the elderly during periods of illness and warm weather

(2009) J. M. G. A. Schols et al.   Journal of Nutrition Health & Aging